Rigel

Decision Resources' Updated Rheumatoid Arthritis Report Now Includes Forecast for Rigel Pharmaceuticals' Fostamatinib Disodium

WALTHAM, Mass., Aug. 6 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, today released its updated Pharmacor Rheumatoid Arthritis report which now includes patient share and sales forecasts through 2018...

Daniel Magilavy, M.D. Joins Rigel as Vice President of Clinical Research

SOUTH SAN FRANCISCO, Calif., Feb. 26 /PRNewswire-FirstCall/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today announced that it has named Daniel B. Magilavy, M.D. vice president of clinical research. In this newly created position, Dr. Magilavy will be responsible for the direction and ove...

Rigel Announces Second Quarter 2009 Financial Results

...RANCISCO, Calif., Aug. 4 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today repo...e 30, 2009. For the second quarter of 2009, rigel reported a net loss of $29.9 million, or $0.81 per...6.7 million and 36.5 million, respectively. rigel reported total operating expenses of $30.0 million...

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi3 Clinical Trial of R788 in Rheumatoid Arthritis

...ANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today anno...e downloads that may be necessary. About rigel (www.rigel.com) rigel is a clinical-stage drug development company that ...

Rigel to Present at Jefferies Healthcare Conference

...ANCISCO, Calif., June 10 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today anno...ftware download that may be necessary. About rigel ( www.rigel.com ) rigel is a clinical-stage drug development company that ...

Rigel's R788 Evaluated in Phase 2 Trial in Multiple Cancers

...RANCISCO, Calif., June 1 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today anno...l occurs. The NCI will conduct the clinical trial, rigel will supply study drug and will receive clinical d...ding R788's therapeutic potential," he added. rigel is presently conducting two Phase 2b clinical tria...

Rigel to Present at JMP Securities Research Conference

...RANCISCO, Calif., May 13 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today anno...ftware download that may be necessary. About rigel ( www.rigel.com ) rigel is a clinical-stage drug development company that ...

Rigel to Present at Barclays Capital Healthcare Conference

...ANCISCO, Calif., March 6 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today anno...ftware download that may be necessary. About rigel ( www.rigel.com ) rigel is a clinical-stage drug development company that ...

Rigel Announces Fourth Quarter and Year End 2008 Financial Results

...ANCISCO, Calif., Feb. 24 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today repo...26/RIGLLOGO ) For the fourth quarter of 2008, rigel reported a net loss of $33.4 million, or $0.91 per...ation of its Phase 1 clinical trial for R343. rigel reported total operating expenses of $34.0 million...

Rigel to Present at BIO CEO & Investor Conference

...ware download that may be necessary. About rigel ( http://www.rigel.com ) rigel is a clinical-stage drug development company that ...ners to develop and market our product candidates. rigel has product development programs in inflammatory/a...

Rigel in Medical Technology

Shareholder Class Action Filed Against Rigel Pharmaceuticals, Inc. by the Law Firm of Barroway Topaz Kessler Meltzer & Check, LLP

RADNOR, Pa., Feb. 20 /PRNewswire/ -- The following statement was issued today by the law firm of Barroway Topaz Kessler Meltzer & Check, LLP: Notice is hereby given that a class action lawsuit was filed in the United States District Court for the Northern District of California on behalf ...

R788 in TASKi3 Clinical Trial Does Not Meet Efficacy Endpoints in RA Patients Who Had Previously Failed Biologic Therapies - Results Incongruent

...ANCISCO, Calif., July 23 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today anno...TASKi trials and appear to be manageable. rigel will host a conference call today at 7PM EDT/ 4PM ...ping the progression of the disease. In July 2009, rigel announced results from its Phase 2b TASKi2 clinica...

Rigel's R788 Significantly Improves Rheumatoid Arthritis in Phase 2b Clinical Trial

...RANCISCO, Calif., July 9 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today anno...irst half of 2010 with a corporate partner. rigel will host a conference call today at 8:00am EDT/5:... Conference Call and Webcast Information rigel will host a conference call to discuss the R788 TA...

Rigel to Host Conference Call to Discuss Results of Its Phase 2b TASKi2 Clinical Trial of R788 in Rheumatoid Arthritis

...RANCISCO, Calif., July 8 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today anno...tware downloads that may be necessary. About rigel ( www.rigel.com ) rigel is a clinical-stage drug development company that ...

Rigel Commences Phase 2 Trial of R788 in Peripheral T-Cell Lymphomas

...NCISCO, Calif., March 13 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today anno...ted in the second half of 2010. In June 2008, rigel first reported results of a Phase 2 clinical trial... http://www.rigel.com/rigel/lymphoma . About rigel ...

Rigel Expects R788 Partnership After Phase 2b Clinical Trials Results

... (MRI) scans as a secondary measure. In addition, rigel will continue to develop R788 in various lymphomas... Conference Call and Webcast Information: rigel will host a conference call today at 8:30 am EST (...are downloads that may be necessary. About rigel ( www.Rigel.com ) ...

Rigel's R788 Phase 2a Results Published in Arthritis and Rheumatism

... were warranted. Phase 2b update In June 2008, rigel initiated two Phase 2b trials of R788 in patients ...rders, please visit the company's website. About rigel (http://www.Rigel.com ) rigel is a clinical-stage drug development company that ...

Preliminary Phase 2 Results of R788 in Lymphoma Show Benefit in Diffuse Large B-Cell and SLL/CLL

...Lymphoma in Lugano, Switzerland later this week. rigel will host a conference call today at 8:00 a.m. EDT...disease is common. Conference Call Information rigel will host a conference call to discuss the lymphom... software downloads that may be necessary. About rigel (http://www.Rigel.com ) ...

Rigel to Host Conference Call to Discuss Preliminary Phase 2 Study Results of R788 in Lymphoma

...t 8:00 a.m. EDT. Participating on the call will be rigel senior management and the principal investigator o...te: http://www.rigel.com/rigel/lymphoma . About rigel ( http://www.rigel.com ) rigel is a clinical-stage drug development company that ...

Rigel's R788 Slows Progression of Murine Lupus in Preclinical Studies

...amage is at risk, immunosuppressant drugs. About rigel ( http://www.Rigel.com ) rigel is a clinical-stage drug development company that ...application in a significant indication each year. rigel has achieved this goal every year since 2002. Our ...

Rigel in Medical Dictionary

Right

...dictionary with ... right -minded. virtuous. More Synonyms " Nearby Words. rigel kentaurus. rigel ... Features a career transition and organizational consulting firm, of...

Rigel in Biological Technology

Poniard Pharmaceuticals Appoints Gary A. Lyons to Board of Directors

...dent of Business Development, Vice President of Sales, and Director of Sales and Marketing. Mr. Lyons currently serves on the Boards of Directors for rigel Pharmaceuticals, Inc., Vical, Incorporated, and Facet Biotech, all publicly held biotechnology companies. Mr. Lyons holds a B.S. in marine biology fr...

Rigel Announces First Quarter 2009 Financial Results

...FRANCISCO, Calif., May 5 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today repo...arch 31, 2009. For the first quarter of 2009, rigel reported a net loss of $29.9 million, or $0.82 per... 36.7 million and 34.4 million, respectively. rigel reported total operating expenses of $30.3 million...

Rigel to Present at Citi's Biotech Day

...NCISCO, Calif., March 27 /PRNewswire-FirstCall/ -- rigel Pharmaceuticals, Inc. (Nasdaq: RIGL ) today anno...ftware download that may be necessary. About rigel ( www.rigel.com ) rigel is a clinical-stage drug development company that ...

Rigel to Participate at the RBC Capital Markets Healthcare Conference

...dequate time for any software download that may be necessary. About rigel ( http://www.rigel.com ) rigel is a clinical-stage drug development company that discovers and develops no...

Rigel to Host Conference Call to Discuss Phase 2 Study Results of R788 in Lymphoma Presented at ASH

...nloads that may be necessary. In addition, rigel will be participating in a plenary session during ...tion: Halls B and C (Moscone Center) About rigel ( http://www.rigel.com ) rigel is a clinical-stage drug development company that ...

Rigel to Present at the 2008 Credit Suisse Healthcare Conference

...sure adequate time for any software download that may be necessary. About rigel ( http://www.rigel.com ) rigel is a clinical-stage drug development company that discovers and develops no...

Rigel Announces Third Quarter 2008 Financial Results and Clinical Update

...ptember 30, 2008. For the third quarter of 2008, rigel reported a net loss of $37.7 million, or $1.03 per...reported in the third quarters of 2008 and 2007. rigel reported operating expenses of $38.7 million in th...8. For the nine months ended September 30, 2008, rigel reported a net loss of $99.0 million, or $2.76 per...

Rigel to Host Update Conference Call

...ure adequate time for any software downloads that may be necessary. About rigel ( http://www.rigel.com ) rigel is a clinical-stage drug development company that discovers and develops no...

Mergent, Inc. Announces Quarterly Rebalancing of HealthShares(TM) Indexes

...CRXX ) DYNAVAX TECHNOLOGIES CORP (NASDAQ: DVAX ) ELAN CORP PLC-ADR (NYSE: ELN ) MEDAREX INC (NASDAQ: MEDX ) PHARMACOPEIA INC. (NASDAQ: PCOP ) rigel PHARMACEUTICALS INC. (NASDAQ: RIGL ) SEPRACOR INC. (NASDAQ: SEPR ) ZYMOGENETICS INC (NASDAQ: ZGEN ) Add ALK-ABELLO A/S (OMX Nordic Exchange C...

VentiRx Pharmaceuticals Appoints Dr. Elliott Grossbard to Board of Directors

... rigel Pharmaceuticals CMO to Add Valuable Clinical Development Expertise SAN DI... Chief Medical Officer at Rigel Pharmaceuticals (Nasdaq: RIGL ). He joined rigel as Senior Vice President of Medical Development in April 2002. Prior to joi...